On September 17, Kang Fang Biotech announced that its self-developed innovative dual-antibody ADC drug AK158D1 has been approved by the Drug Evaluation Center of the State Drug Administration to conduct phase I clinical studies for the treatment of advanced malignant solid tumors.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.